Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916887 | 0.78 | NOS2 (0.40) | NOS2TDP1TSHR | |
| SCHEMBL29168794 | 0.76 | KDM4E (0.30) | — | |
| SCHEMBL1535121 | 0.71 | TSHR (0.47) | TDP1TSHR | |
| SCHEMBL12915076 | 0.68 | TSHR (0.44) | TDP1TSHR | |
| SCHEMBL19450283 | 0.68 | TSHR (0.44) | TDP1TSHR | |
| SCHEMBL14969788 | 0.68 | TSHR (0.44) | TDP1TSHR | |
| SCHEMBL12560763 | 0.68 | TSHR (0.44) | TDP1TSHR | |
| SCHEMBL19449972 | 0.68 | TSHR (0.44) | TDP1TSHR | |
| SCHEMBL19450212 | 0.68 | TSHR (0.44) | TDP1TSHR | |
| SCHEMBL2787443 | 0.66 | TSHR (0.41) | TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301924-B1 | METHOD FOR PRODUCING 2,4,6-TRIS(HYDROXYPHENYL)-1,3,5-TRIAZINE COMPOUND | ADEKA CORP (JP) | 2015-09-02 | — | — | EP | disclosed |
| EP-2573076-B1 | Method for producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound | ADEKA CORP (JP) | 2014-08-20 | — | — | EP | disclosed |
| US-8716474-B2 | Method for producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound | ADEKA CORPORATION (JP) | 2014-05-06 | — | — | US | disclosed |
| EP-2573076-A1 | Method for producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound | Adeka Corporation (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20110087023-A1 | METHOD FOR PRODUCING 2,4,6-TRIS(HYDROXYPHENYL)-1,3,5-TRIAZINE COMPOUND | ADEKA CORPORATION (JP) | 2011-04-14 | — | — | US | disclosed |
| EP-2301924-A1 | METHOD FOR PRODUCING 2,4,6-TRIS(HYDROXYPHENYL)-1,3,5-TRIAZINE COMPOUND | Adeka Corporation (JP) | 2011-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087023-A1 | METHOD FOR PRODUCING 2,4,6-TRIS(HYDROXYPHENYL)-1,3,5-TRIAZINE COMPOUND | QSOX1, TST, TH | NOS2 1378/4885TDP1 2919/4885TSHR 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.